Claims
- 1. A method of enhancing the response of a tumor to irradiation, comprising:a) administering to a patient in need of such therapy a radiosensitizing amount of a pharmaceutical composition comprising paclitaxel, docetaxel, eptopside, teniposide, camptothecin or epothilone conjugated to a water soluble polyamino acid polymer and a pharmaceutically acceptable carrier; b) irradiating said tumor; wherein said conjugated paclitaxel or docetaxel have increased water solubility, efficacy and accumulation within a tumor compared with the corresponding unconjugated drugs.
- 2. The method of claim 1, wherein said polymer is selected form polyglutamic acids, polyaspartic acids or polylysines.
- 3. The method of claim 1, wherein said polymer is a polyglutamic acid.
- 4. The method of claim 3, wherein said conjugate comprises from about 2% to about 35% by weight of paclitaxel or docetaxel.
- 5. The method of claim 1, wherein step (b) is carried out by administering gamma irradiation to said tumor.
- 6. The method of claim 1, wherein said composition is administered prior to irradiation.
- 7. The method of claim 1, wherein said composition is administered following irradiation.
- 8. The method of claim 1, wherein said irradiation dose is about 10 Gray per week, and said composition is administered within 1-2 of irradiation.
- 9. The method of claim 1, wherein said cancer is breast cancer, ovarian cancer, malignant melanoma, lung cancer, gastric cancer, prostate cancer, colon cancer, head and neck cancer; leukemia or Kaposi's sarcoma.
- 10. A method of treating cancer comprising:a) administering to a patient in need of such therapy a radiosensitizing amount of a pharmaceutical composition comprising paclitaxel, docetaxel, eptopside, teniposide, camptothecin or epothilone conjugated to a polyglutamic acid polymer and a pharmaceutically acceptable carrier; and b) irradiating said tumor.
- 11. The method of claim 10, wherein the amount of said composition is from about 0.5 times to about 2 times the maximum tolerated doses of paclitaxel in equivalent paclitaxel doses.
- 12. The method of claim 1, wherein said conjugate is a paclitaxel conjugate.
- 13. The method of claim 12, wherein said polymer is selected from polyglutamic acid, polyaspartic acid or polylysine.
- 14. The method of claim 12, wherein said polymer is polyglutamic acid.
- 15. The method of claim 14, wherein step (b) is carried out by administering gamma irradiation to said tumor.
- 16. The method of claim 1, wherein said conjugate is a docetaxel conjugate.
- 17. The method of claim 16, wherein said polymer is selected from polyglutamic acid, polyaspartic acid or polylysine.
- 18. The method of claim 16, wherein said polymer is polyglutamic acid.
- 19. The method of claim 18, wherein step (b) is carried out by administering gamma irradiation to said tumor.
- 20. The method according to claim 1, wherein said pharmaceutical composition is administered parenterally.
- 21. The method according to claim 1, wherein said pharmaceutical composition is administered intraperitoneally.
- 22. The method according to claim 1, wherein said pharmaceutical composition is administered intravenously.
- 23. The method according to claim 14, wherein said pharmaceutical composition is administered parenterally.
- 24. The method according to claim 14, wherein said pharmaceutical composition is administered intraperitoneally.
- 25. The method according to claim 14, wherein said pharmaceutical composition is administered intravenously.
Parent Case Info
This application is a continuation of Ser. No. 07/530,601 filed Jan. 11, 2001 now abandoned, which is a 371 of PCT/US99/06870, filed Mar. 30, 1999, which is a continuation-in-part of U.S. Ser. No. 09/050,662 filed Mar. 30, 1998 U.S. Pat. No. 6,441,025.
US Referenced Citations (8)
Number |
Name |
Date |
Kind |
5473055 |
Mongelli et al. |
Dec 1995 |
A |
5626862 |
Brem et al. |
May 1997 |
A |
5730968 |
Butterfield et al. |
Mar 1998 |
A |
5776925 |
Young et al. |
Jul 1998 |
A |
5846565 |
Brem, II et al. |
Dec 1998 |
A |
6127355 |
Greenwald et al. |
Oct 2000 |
A |
6218367 |
Jacob |
Apr 2001 |
B1 |
6262107 |
Li et al. |
Jul 2001 |
B1 |
Non-Patent Literature Citations (3)
Entry |
Li et al., “Enhancement of Tumor Radioresponse of A Murine Ovarian Carcinoma By Poly(L-Glutamic Acid)-Paclitaxel Conjugate”, CTI 9th Annual International Symposium on Recent Advances in Drug Delivery Systems, Feb. 22-25, 1999, (2 pages). |
Ke et al., “Schedule-Independent Radiosensitization of a Murine Ovarian Oca-1 Tumor by PG-TXL”, CTI Proceedings of the American Association for Cancer Research, vol. 40, # 4223, Ref. 248, Mar. 1999 (1 page). |
Li et al., “Water-Soluble Polyglutamic Acid-Paclitaxel Conjugate (PGA-Paclitaxel): Antitumor Regression in Rats Braeing 13762 Mammary Carcinoma”, Pharmaceutical Research, Sep. 1996, vol. 13, No. 9, p. S-368, Abstract PDD 7541, see entire abstract. |
Continuations (1)
|
Number |
Date |
Country |
Parent |
09/530601 |
|
US |
Child |
10/153818 |
|
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
09/050662 |
Mar 1998 |
US |
Child |
09/530601 |
|
US |